Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Lung Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Penile Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Lymphoma 1Carcinoma, Neuroendocrine 1

Interventions

Temozolomide 12Vincristine 9Irinotecan 8Cyclophosphamide 8cabozantinib 6X-Rays 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Etoposide 5regorafenib 4fludarabine 4Radiotherapy 4Phantoms, Imaging 4Ifosfamide 4Doxorubicin 4Radiation 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2liposomal doxorubicin 2ivosidenib 2irinotecan sucrosofate 2etoposide phosphate 2abemaciclib 2Zoledronic Acid 2Topotecan 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × BAY 1895344 × 1 year × Clear all
NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
31 enrolled 14 charts
LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡